BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33502831)

  • 1. A Vaccination with Boosted Cross Presentation by ER-Targeted Antigen Delivery for Anti-Tumor Immunotherapy.
    Shi Y; Zhu C; Liu Y; Lu Y; Li X; Qin B; Luo Z; Luo L; Jiang M; Zhang J; Guan G; Zheng C; You J
    Adv Healthc Mater; 2021 Apr; 10(8):e2001934. PubMed ID: 33502831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced endoplasmic reticulum entry of tumor antigen is crucial for cross-presentation induced by dendritic cell-targeted vaccination.
    Wang H; Yu X; Guo C; Zuo D; Fisher PB; Subjeck JR; Wang XY
    J Immunol; 2013 Dec; 191(12):6010-21. PubMed ID: 24218449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
    Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
    J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response.
    Song C; Noh YW; Lim YT
    Int J Nanomedicine; 2016; 11():3753-64. PubMed ID: 27540289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response.
    Liu X; Liu J; Liu D; Han Y; Xu H; Liu L; Leng X; Kong D
    Biomater Sci; 2019 Dec; 7(12):5516-5527. PubMed ID: 31670734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells.
    Imai J; Hasegawa H; Maruya M; Koyasu S; Yahara I
    Int Immunol; 2005 Jan; 17(1):45-53. PubMed ID: 15546887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens.
    Gao J; Ochyl LJ; Yang E; Moon JJ
    Int J Nanomedicine; 2017; 12():1251-1264. PubMed ID: 28243087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.
    Santone M; Aprea S; Wu TY; Cooke MP; Mbow ML; Valiante NM; Rush JS; Dougan S; Avalos A; Ploegh H; De Gregorio E; Buonsanti C; D'Oro U
    Hum Vaccin Immunother; 2015; 11(8):2038-50. PubMed ID: 26024409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation.
    Hirosue S; Kourtis IC; van der Vlies AJ; Hubbell JA; Swartz MA
    Vaccine; 2010 Nov; 28(50):7897-906. PubMed ID: 20934457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active dissemination of cellular antigens by DCs facilitates CD8
    Gurevich I; Feferman T; Milo I; Tal O; Golani O; Drexler I; Shakhar G
    Eur J Immunol; 2017 Oct; 47(10):1802-1818. PubMed ID: 28872666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
    Cioca DP; Deak E; Cioca F; Paunescu V
    J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
    Adams EW; Ratner DM; Seeberger PH; Hacohen N
    Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes.
    Fu C; Peng P; Loschko J; Feng L; Pham P; Cui W; Lee KP; Krug AB; Jiang A
    Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23730-23741. PubMed ID: 32879009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells.
    Tagliani E; Guermonprez P; Sepúlveda J; López-Bravo M; Ardavín C; Amigorena S; Benvenuti F; Burrone OR
    J Immunol; 2008 Mar; 180(5):3201-9. PubMed ID: 18292544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular heat shock protein 90 plays a role in translocating chaperoned antigen from endosome to proteasome for generating antigenic peptide to be cross-presented by dendritic cells.
    Oura J; Tamura Y; Kamiguchi K; Kutomi G; Sahara H; Torigoe T; Himi T; Sato N
    Int Immunol; 2011 Apr; 23(4):223-37. PubMed ID: 21421737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses.
    Liu J; Liu X; Han Y; Zhang J; Liu D; Ma G; Li C; Liu L; Kong D
    ACS Appl Mater Interfaces; 2018 Sep; 10(37):30983-30993. PubMed ID: 30136844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.